SCHEMBL2679124

SCHEMBL2679124

Cc1ccc(C(=O)Nc2cccc(F)c2)cc1NC(=O)C=Cc1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.56
CSF1R P07333 2/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
GALR2 O43603 1/20 0.55
HPGD P15428 1/20 0.55
RECQL P46063 1/20 0.55
NAMPT P43490 9/20 0.54
HDAC1 Q13547 4/20 0.54
HDAC3 O15379 3/20 0.54
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
HDAC4 P56524 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077757 1.00 BRAF (0.56) BRAFCSF1RLMNAMAPTKMT2A
SCHEMBL2679261 0.90 NAMPT (0.64) LMNAMAPTKMT2AMEN1GALR2
SCHEMBL10077687 0.90 NAMPT (0.64) LMNAMAPTKMT2AMEN1GALR2
SCHEMBL10077766 0.90 LCK (0.56) BRAFCSF1RMAPTHDAC1HDAC3
SCHEMBL2678891 0.90 LCK (0.56) BRAFCSF1RMAPTHDAC1HDAC3
SCHEMBL2680476 0.90 NAMPT (0.63) BRAFCSF1RLMNAMAPTKMT2A
SCHEMBL10078409 0.90 NAMPT (0.63) BRAFCSF1RLMNAMAPTKMT2A
SCHEMBL10054800 0.89 NAMPT (0.64) BRAFCSF1RLMNAMAPTKMT2A
SCHEMBL2678914 0.89 NAMPT (0.64) BRAFCSF1RLMNAMAPTKMT2A
SCHEMBL10077740 0.88 CSF1R (0.73) BRAFCSF1RMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR BRAF 21/4885CSF1R 2608/4885LMNA 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.